CCL27 and neoplasm: In a multivariable model including tumor size, number of positive nodes, receptor subtype, and treatment type, patients with concurrent ILC + LCIS had significantly improved RFS compared to those with ILC-alone among patients with pleomorphic subtype (HR 0.15, 95% confidence interval (CI) 0.04–0.62.04.62, p < 0.009, Table 7).